About Serum paraoxonase/arylesterase 2
Serum paraoxonase/arylesterase 2 (PON2) is a protein
from Homo sapiens identified by UniProt accession
Q15165, 354 residues long.
MolForge cross-references it against 0 known binders and
198 disease associations.
Target properties
| Protein name | Serum paraoxonase/arylesterase 2 |
|---|
| UniProt accession | Q15165 |
|---|
| Gene | PON2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 354 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (198)
Diseases linked to this target (Open Targets).
- Amyotrophic lateral sclerosis · score 0.37
- amyotrophic lateral sclerosis · score 0.37
- neoplasm · score 0.10
- type 2 diabetes mellitus · score 0.09
- Systemic lupus erythematosus · score 0.08
- glioblastoma multiforme · score 0.08
- angioimmunoblastic T-cell lymphoma · score 0.07
- cholesterol-ester transfer protein deficiency · score 0.07
- hypertriglyceridemia 2 · score 0.06
- Blackfan-Diamond anemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15165-F1 | alphafold | PREDICTED | 96.91 | — |
Amino-acid sequence (354 residues)
MGRLVAVGLL GIALALLGER LLALRNRLKA SREVESVDLP HCHLIKGIEA GSEDIDILPN GLAFFSVGLK FPGLHSFAPD KPGGILMMDL KEEKPRAREL RISRGFDLAS FNPHGISTFI DNDDTVYLFV VNHPEFKNTV EIFKFEEAEN SLLHLKTVKH ELLPSVNDIT AVGPAHFYAT NDHYFSDPFL KYLETYLNLH WANVVYYSPN EVKVVAEGFD SANGINISPD DKYIYVADIL AHEIHVLEKH TNMNLTQLKV LELDTLVDNL SIDPSSGDIW VGCHPNGQKL FVYDPNNPPS SEVLRIQNIL SEKPTVTTVY ANNGSVLQGS SVASVYDGKL LIGTLYHRAL YCEL
Explore Serum paraoxonase/arylesterase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets